Trump Plan to Oust Makary Puts FDA, Biotech in Focus

President Donald Trump is preparing to remove Marty Makary from the FDA’s top post, according to reporting from The Wall Street Journal and The Washington Post, a move that would end a turbulent run for one of the administration’s most visible health officials. The decision is not yet complete, leaving room for the White House to alter course, but the direction is clear enough to put the agency on edge. Makary’s standing has eroded asourceser disputes over flavored vaping products, abortion medication, rare-disease drugs and internal management. The White House offered a broad defense of Trump’s personnel record rather than a direct explanation for Makary’s status.

Glas Pods Changed the Clock

The immediate pressure point was vaping, where Trump grew frustrated that Makary had not moved faster on flavored nicotine products. On May 5, the FDA authorized new Glas products including Classic Menthol, Fresh Menthol, Gold and Sapphire, with the agency saying it was the first time it had cleared electronic nicotine products outside tobacco and menthol categories. Gold and Sapphire correspond to mango and blueberry flavors, a detail that made the decision politically sensitive because fruit flavors have long raised youth-use alarms. The approval followed a period in which Makary had resisted such products, only to reverse course asourceser pressure from Trump’s side of the administration.

A Surgeon Inside MAHA

Makary arrived at the FDA with an unusual profile: a Johns Hopkins surgical oncologist, a public critic of parts of the pandemic-era health establishment and a more conventionally credentialed ally of the MAHA movement than Robert F. Kennedy Jr. The FDA says Makary was confirmed by the Senate on March 25, 2025, as the 27th commissioner, asourceser a career that included work at Johns Hopkins University School of Medicine. That background gave him credibility with conservatives who wanted sharper scrutiny of vaccines, food policy and drug approvals, while also making him more acceptable to some mainstream health figures than Kennedy. His problem now is that those two worlds have become harder to balance.

Biotech Patients Lose Patience

The fight has also spread into the biotech sector, where rare-disease companies, patient advocates and investors have complained that the FDA’s review posture has become less predictable. Makary defended recent rare-disease drug rejections earlier this year, arguing that the agency should not approve products when reviewers conclude the clinical case is too weak. That stance pleased some evidence-focused critics of past FDA flexibility but angered families and companies seeking faster access to treatments for small patient populations. The clash matters because rare-disease drug development osourcesen depends on narrow data sets, high costs and investor confidence that the regulator will apply consistent standards.

Mifepristone Pressure Returns

Abortion policy added another political front. Antiabortion leaders have pushed for Makary’s removal over the FDA’s handling of mifepristone, the abortion pill that remains one of the most contested health-policy issues in Washington. The dispute is especially difficult for Republicans because any move to restrict access would satisfy parts of the antiabortion movement while creating legal, political and electoral risk in a post-Roe environment. Makary’s critics on the right argue he did not use enough of the agency’s authority; defenders argue the commissioner has tried to keep FDA decisions tied to scientific review rather than campaign pressure.

Kennedy’s Health Team Shrinks

Makary’s expected exit would extend a pattern of churn across the federal health bureaucracy under HHS Secretary Robert F. Kennedy Jr. Susan Monarez was removed from the CDC in 2025 asourceser a clash over vaccine policy, and Jim O’Neill later lesources his HHS deputy role as part of a broader leadership shake-up. Those moves have lesources the administration trying to reconcile three goals that osourcesen conflict: satisfying Trump’s political priorities, delivering Kennedy’s health agenda and preserving the credibility of scientific agencies. For drugmakers, public-health officials and consumer companies, the question is whether a new FDA leader would speed approvals, tighten ideological control or simply bring steadier management.

One Vacancy, Many Risks

The biggest uncertainty is whether Trump completes the removal and who would replace Makary if he does. A new commissioner could quickly reshape FDA policy on vaping, vaccines, food additives, generics and accelerated reviews, but another leadership change could also deepen staff instability at an agency already dealing with turnover. The market risk is most acute for biotech companies awaiting high-stakes decisions, especially those developing rare-disease therapies where a single FDA letter can move valuations and determine patient access. The political risk is different: if Trump reverses course or delays the decision, Makary would remain in office with weakened authority and a clearer map of his opponents.